Diabetes and acute coronary syndrome
Related Experiment Video
Updated: Jun 13, 2026
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
P F Keller1, D Carballo, M Roffi
1Division of Cardiology, Geneva University Hospital, Geneva, Switzerland. pierre-frederic.keller@hcuge.ch
Insights
Diabetic patients with acute coronary syndromes (ACS) face higher risks but benefit more from aggressive therapies like platelet inhibition and early invasive strategies. Balancing treatment with bleeding risk is crucial for better outcomes.
Area of Science:
- Cardiology
- Endocrinology
- Public Health
Background:
- Diabetes is a growing health concern in Western countries, increasing cardiovascular event risk.
- Diabetic patients with acute coronary syndromes (ACS) are prone to proatherosclerotic, proinflammatory, and prothrombotic states.
- Despite risks, diabetic individuals experience greater benefits from evidence-based ACS therapies.
Purpose of the Study:
- To outline optimal evidence-based therapeutic strategies for diabetic patients experiencing ACS.
- To highlight the importance of aggressive antiplatelet and invasive approaches in this high-risk population.
- To emphasize secondary preventive measures and the need for equitable treatment delivery.
Main Methods:
- Review of current evidence on managing acute coronary syndromes (ACS) in diabetic patients.
- Analysis of therapeutic mainstays: aggressive platelet inhibition and early invasive strategies.
- Consideration of specific agents like aspirin, prasugrel, and glycoprotein IIb/IIIa inhibitors.
- Evaluation of revascularization techniques, including percutaneous coronary intervention (PCI) and radial approach.
- Assessment of secondary preventive measures: statins, ACE inhibitors/ARBs, and glucose control.
Main Results:
- Diabetic ACS patients benefit significantly from early invasive strategies and aggressive platelet inhibition (prasugrel preferred over clopidogrel).
- Early coronary angiography and revascularization show greater benefit in diabetics with non-ST-segment elevation ACS.
- Primary PCI is the standard for ST-segment elevation myocardial infarction in all patients.
- Radial approach for PCI access is recommended to minimize bleeding complications.
- Despite proven efficacy, diabetic patients less frequently receive guideline-recommended ACS treatments.
Conclusions:
- Aggressive antiplatelet therapy and early invasive management are critical for diabetic ACS patients.
- Balancing antithrombotic intensity with bleeding risk is essential for personalized care.
- Effective secondary prevention, including statins, ACE inhibitors/ARBs, and glucose control, is vital.
- Addressing disparities in treatment delivery is necessary to improve outcomes for diabetic ACS patients.
Abstract:
Contrary to the decline in the prevalence of several risk factors such as hypertension, hypercholesterolemia and smoking, diabetes is an expanding health burden in the Western world. Because of the proatherosclerotic, proinflammatory, and prothrombotic states associated with diabetes, diabetic patients with acute coronary syndromes (ACS) are at high risk of subsequent cardiovascular events. However, they derive at the same time greater benefit from evidence-based therapy than the non-diabetic individuals. The two mainstays of acute ACS therapy for diabetic patients are an aggressive platelet inhibition and an early invasive strategy. Aspirin should be administered in all patients and prasugrel is to be considered superior to clopidogrel in this setting. While the use of glycoprotein IIb/IIIa receptor inhibitors in the diabetic ACS population has been associated with a mortality reduction, the role of these agents in the prasugrel era remains to be elucidated. Importantly, the aggressiveness of anti-thrombotic therapy should be balanced in each individual patient with the risk of bleeding. The benefit of early coronary angiography and, if needed, revascularization, in the setting of non-ST-segment elevation ACS is more pronounced in diabetic than in non-diabetic individuals. All patients, diabetics and non-diabetics, qualify for primary percutaneous coronary intervention (PCI) as the therapy of choice for ST-segment elevation myocardial infarction. In order to reduce hemorrhagic complications related to vascular access for PCI, the radial approach should be favored. Additional important secondary preventive measures include high-dose statin therapy, ACE-Inhibition/angiotensin II receptor blockade, and adequate glucose metabolism control. Despite the documented efficacy, diabetic patients with ACS receive evidence-based treatments less frequently than non-diabetic individuals.
Related Concept Videos
01:22Complications of Diabetes Mellitus
01:26Acute Coronary Syndrome V: Nursing Management
01:30Acute Coronary Syndrome I: Introduction
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:28Acute Coronary Syndrome IV: Interprofessional Care